Navigation Links
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Trius Therapeutics, Inc. - TSRX
Date:7/31/2013

NEW YORK, July 31, 2013 /PRNewswire/ -- Pomerantz Grossman Hufford Dahlstrom & Gross LLP is investigating claims on behalf of investors of Trius Therapeutics, Inc. ("Trius" or the "Company") (NASDAQ: TSRX) (ISIN: US89685K1007) (CUSIP: 89685K100) concerning the proposed acquisition of Trius by Cubist Pharmaceuticals, Inc. in a transaction valued at $818 million.

The investigation concerns whether the Trius directors are breaching their fiduciary duties by failing to adequately shop the Company and maximize shareholder value.  Under the terms of the agreement, Trius shareholders will be entitled to receive $13.50 per share in cash for each share of Trius common stock. In addition to the upfront cash payment, each Trius stockholder will receive one Contingent Value Right, entitling the holder to receive an additional cash payment of up to $2.00 for each share they own if certain commercial sales milestones are achieved.  However, the price to Revenue and Book Value multiples are below the averages of comparable transactions and at least one analyst has set a target price of $20.00 per share for Trius common stock.

Trius shareholders seeking more information about this acquisition are advised to contact Robert Willoughby at rswilloughby@pomlaw.com or 212-661-1100 or 888-476-6529, ext. 237.

The firm is also investigating actions on behalf of shareholders for the following companies:  Hilltop Community Bancorp, Inc., Dole Food Company, Inc., and Cooper Tire & Rubber Company.

The Pomerantz Firm, with offices in New York, Chicago, Florida, and San Diego, is acknowledged as one of the premier firms in the areas of corporate, securities,
'/>"/>

SOURCE Pomerantz Grossman Hufford Dahlstrom & Gross LLP
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Royalty Pharma Notes Elan Sales Process Offers Shareholders No Certainty
2. Adamis Pharmaceuticals CEO Provides Update for Shareholders
3. SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces Investigation into Possible Breaches of Fiduciary Duty by the Board of PROLOR Biotech, Inc. in Connection with the Sale of the Company to OPKO Health, Inc.
4. 3SBio Inc. Adjourns Extraordinary General Meeting of Shareholders
5. SHAREHOLDER ALERT: The Law Firm of Levi & Korsinsky Notifies Investors with Losses on Their Investment in Incyte Corporation of Class Action Lawsuit and the May 6, 2013 Lead Plaintiff Deadline
6. Hadasit Bio-Holdings CEO Letter to Shareholders
7. Medifirst Solutions, Inc. Announces Further Update To Shareholders
8. Letter from Alliqua CEO, Dave Johnston, to Shareholders
9. TPI to Hold 2012 Shareholder Annual Meeting on May 8, 2013 In New York City
10. EastBridge Investment Group Announces Completion of its Merger with Cellular Biomedicine Group - Shareholder Conference Call to be held February 8th
11. Cell Therapeutics, Inc.s (CTI) Board of Directors Approves Amendment of Shareholder Rights Plan
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/22/2014)... Fertility Associates of Memphis has announced a new ... network of more than 20 contributing fertility practices ... access to a national pool of frozen donor ... of Memphis is the only fertility clinic in the ... Dr. William Kutteh , director of Fertility Associates of ...
(Date:12/19/2014)... Dec. 19, 2014 Naurex Inc., a biopharmaceutical ... for diseases of the central nervous system, today announced ... executive officer, will present at the 33 rd ... take place at 3:00 p.m. PST on Tuesday, January ... San Francisco, Calif. ...
(Date:12/19/2014)... , Dec. 19, 2014 Research and ... the addition of the "Technology Innovations in ... offering. http://photos.prnewswire.com/prnh/20130307/600769 ... in Smart Fabrics" offers a detailed assessment on ... Key Findings: 1. The ...
(Date:12/19/2014)... Ed Bilsky, Ph.D., vice president for Research ... in the Neurosciences (CEN), and professor of pharmacology at ... a member of the prestigious Dana Alliance for Brain ... to receive this honor. , The Dana Alliance ... Dana Foundation. Its mission is to advance public ...
Breaking Biology Technology:Fertility Associates of Memphis Announces Partnership with Donor Egg Bank USA 2Fertility Associates of Memphis Announces Partnership with Donor Egg Bank USA 3Naurex to Present at 33rd Annual J.P. Morgan Healthcare Conference 2Technology Innovations in Smart Fabrics (Technical Insights) 2UNE's Ed Bilsky Named Member of Dana Alliance for Brain Initiatives 2UNE's Ed Bilsky Named Member of Dana Alliance for Brain Initiatives 3
... Inc. (OTC Bulletin Board: LIXT) today announced the,trading of ... Symbol LIXT. Commenting on this important milestone, President ... being a publicly traded company will,enable us to pursue ... private company. Having access to the capital markets is ...
... of HPV Viral Load a Possible Indicator of Cervical ... ... 24 Cepheid (Nasdaq:,CPHD) today announced that it has entered into ... by Quantovir,AB of Sweden for the quantitative measurement of high-risk HPV ...
... - Follows the Companies, Previous Announcement of MGCD0103,s ... Lymphoma in the United States -, BOULDER, ... PHRM ) and MethylGene, Inc. (TSX: MYG) ... the European,Commission (EC) designated MGCD0103, a histone deacetylase ...
Cached Biology Technology:Lixte Biotechnology Holdings, Inc. Announces the Initial Trading of Its Common Stock Under the Symbol: LIXT 2Lixte Biotechnology Holdings, Inc. Announces the Initial Trading of Its Common Stock Under the Symbol: LIXT 3Lixte Biotechnology Holdings, Inc. Announces the Initial Trading of Its Common Stock Under the Symbol: LIXT 4Cepheid Enters Agreement To Exclusively License HPV Portfolio Developed by Quantovir AB 2Cepheid Enters Agreement To Exclusively License HPV Portfolio Developed by Quantovir AB 3Cepheid Enters Agreement To Exclusively License HPV Portfolio Developed by Quantovir AB 4Pharmion and MethylGene Announce Orphan Drug Designation Granted by the European Medicines Agency (EMEA) for MGCD0103 for the Treatment of Hodgkin's Lymphoma 2Pharmion and MethylGene Announce Orphan Drug Designation Granted by the European Medicines Agency (EMEA) for MGCD0103 for the Treatment of Hodgkin's Lymphoma 3Pharmion and MethylGene Announce Orphan Drug Designation Granted by the European Medicines Agency (EMEA) for MGCD0103 for the Treatment of Hodgkin's Lymphoma 4
(Date:12/17/2014)... DUBLIN , Dec. 15, 2014 Research ... announced the addition of the "Samsung Galaxy ... Analysis" report to their offering. ... on a totally different sensing technology than the ... a fingerprint sensor in its product. ...
(Date:12/17/2014)... -- Valencell, a leader in performance biometric data sensor ... leaders such as Intel, Jabra, Atlas, and Scosche to ... These products will be showcased at CES 2015, taking ... . "Our partners choose PerformTek biometrics, ... with the clinical data to back it up," said ...
(Date:12/15/2014)... 2014 Research and Markets ( ... "Global Facial Recognition Market 2015-2019" report ... http://photos.prnewswire.com/prnh/20130307/600769 Facial recognition is a ... recognition system measures the overall facial feature of ... and the distance between eyes. Facial recognition is ...
Breaking Biology News(10 mins):Samsung Galaxy S5 - Home Button Synaptics Fingerprint Sensor Technology Analysis 2Valencell PerformTek Biometrics Power the Most Accurate Wearables at CES 2015 2Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 2Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 3
... Escherichia coli, one of the best-studied single-celled organisms ... be thought of as a factory with just one product: ... business plan is to make them at the lowest possible ... case of a bacterium, can be defined by the energy ...
... ancient relative of modern humans may have evolved to ... as part of a survival strategy, according to a ... includes Florida State University,s Dennis E. Slice. The ... National Academy of Science, challenge a long-standing hypothesis ...
... to return to Russia to oversee preparations for the launch ... 16 March 2009. This follows implementation of the corrective measures ... launch of GOCE by Eurockot Launch Services last October. ... Plesetsk Cosmodrome in northern Russia to arrange logistical matters while ...
Cached Biology News:Bacteria are models of efficiency 2March launch planned for ESA's gravity mission 2